Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study

Author:

Wu Yi‐Long1ORCID,Zhang Li2,Fan Yun3,Zhou JianYing4,Zhang Li5,Zhou Qing1,Li Wei6,Hu ChengPing7,Chen GongYan8,Zhang Xin9,Zhou CaiCun10,Dang Thao11,Sadowski Sara11,Kush Debra A.11,Zhou Yu12,Li Ben12,Mok Tony13

Affiliation:

1. Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences Guangzhou China

2. Peking Union Medical College Hospital Beijing China

3. The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou China

4. The First Affiliated Hospital of Zhejiang University Hangzhou China

5. Sun Yat‐Sen University Cancer Center Guangzhou China

6. The First Hospital of Jilin University Changchun China

7. Xiangya Hospital—Central South University Changsha China

8. The Third Affiliated Hospital of Harbin Medical University Harbin China

9. Zhongshan Hospital Fudan University Respiratory Diseases Department Shanghai China

10. Shanghai Pulmonary Hospital and Tongji University School of Medicine Shanghai China

11. Merck & Co., Inc. Kenilworth New Jersey USA

12. MSD China Shanghai China

13. State Key Laboratory of Translation Oncology Chinese University of Hong Kong Hong Kong China

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3